CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany

Patients with precursor B-cell acute lymphoblastic leukemia (pB-ALL) who have relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT), have relapsed more than once, or are resistant upfront have a dismal prognosis. CD19-targeted chimeric antigen receptor (CAR) T cells have evol...

Descripción completa

Detalles Bibliográficos
Autores principales: Bader, Peter, Rossig, Claudia, Hutter, Martin, Ayuk, Francis Ayuketang, Baldus, Claudia D., Bücklein, Veit L., Bonig, Halvard, Cario, Gunnar, Einsele, Hermann, Holtick, Udo, Koenecke, Christian, Bakhtiar, Shahrzad, Künkele, Annette, Meisel, Roland, Müller, Fabian, Müller, Ingo, Penack, Olaf, Rettinger, Eva, Sauer, Martin G., Schlegel, Paul-Gerhardt, Soerensen, Jan, von Stackelberg, Arend, Strahm, Brigitte, Hauer, Julia, Feuchtinger, Tobias, Jarisch, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242498/
https://www.ncbi.nlm.nih.gov/pubmed/36607834
http://dx.doi.org/10.1182/bloodadvances.2022008981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242498/
https://www.ncbi.nlm.nih.gov/pubmed/36607834
http://dx.doi.org/10.1182/bloodadvances.2022008981

Ejemplares similares